Full Press Release Details
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases Regeneron Retains U.S. Commercialization Rights, Receives.
REGN
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases Regeneron Retains U.S. Commercialization Rights, Receives
Key Takeaway: Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases Regeneron Retains U.S. Commercialization Rights, Receives
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema